Octhilinone

Octhilinone



Associated High Confidence AOPs
For more information or term definitions, please refer to HELP page.

Associated AOPs with Level of Relevance 1
AOP Identifier AOP Title AO Classification OECD Status Coverage Score KE Identifier KE Name
AOP:15Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutationsGenetic DiseaseWPHA/WNT Endorsed0.25KE:155Inadequate DNA repair
AOP:18PPARα activation in utero leading to impaired fertility in malesReproductive System DiseaseUnder Review0.12KE:289Decrease, Translocator protein (TSPO)
AOP:42Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in MammalsCognitive DisorderWPHA/WNT Endorsed0.12KE:277Thyroid hormone synthesis, Decreased
AOP:54Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairmentDevelopmental Disorder Of Mental HealthWPHA/WNT Endorsed0.1KE:277Thyroid hormone synthesis, Decreased
AOP:60NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosisGastrointestinal System Disease; Inherited Metabolic Disorder-0.08KE:474Down Regulation, HMGCS2
AOP:107Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the ratCancer; Gastrointestinal System DiseaseUnder Review0.2KE:1214Altered gene expression specific to CAR activation, Hepatocytes
AOP:108Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat)Cancer; Gastrointestinal System Disease-0.17KE:768Increase, Cytotoxicity
AOP:110Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse)Cancer; Endocrine System Disease-0.14KE:277Thyroid hormone synthesis, Decreased
AOP:119Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse)Cancer; Endocrine System Disease-0.14KE:277Thyroid hormone synthesis, Decreased
AOP:122Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formationUnclassified-0.1KE:799Increased, HIF-1 heterodimer
AOP:134Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in MammalsCognitive Disorder-0.11KE:277Thyroid hormone synthesis, Decreased
AOP:136Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal TumorsBenign Neoplasm; Respiratory System DiseaseUnder Review0.14KE:768Increase, Cytotoxicity
AOP:139Alkylation of DNA leading to cancer 1Cancer-0.25KE:155Inadequate DNA repair
AOP:159Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflationUnclassifiedWPHA/WNT Endorsed0.12KE:277Thyroid hormone synthesis, Decreased
AOP:175Thyroperoxidase inhibition leading to altered amphibian metamorphosisUnclassified-0.25KE:277Thyroid hormone synthesis, Decreased
AOP:176Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosisUnclassified-0.2KE:277Thyroid hormone synthesis, Decreased
AOP:188Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosisUnclassified-0.2KE:277Thyroid hormone synthesis, Decreased
AOP:190Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosisUnclassified-0.17KE:1829Altered, Thyroid hormone-dependent gene expression
AOP:191Type III iodotyrosine deiodinase (DIO3) inhibition leading to altered amphibian metamorphosisUnclassified-0.5KE:1154Increased, Triiodothyronine (T3) in tissues
KE:1829Altered, Thyroid hormone-dependent gene expression
AOP:192Pendrin inhibition leading to altered amphibian metamorphosisUnclassified-0.25KE:277Thyroid hormone synthesis, Decreased
AOP:193Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosisUnclassified-0.25KE:277Thyroid hormone synthesis, Decreased
AOP:207NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegansReproductive System Disease-0.12KE:1280Activation, HIF-1
AOP:232NFE2/Nrf2 repression to steatosisGastrointestinal System Disease; Inherited Metabolic Disorder-0.12KE:1419Reduced, FXR activity
AOP:271Inhibition of thyroid peroxidase leading to impaired fertility in fishUnclassifiedUnder Development0.2KE:277Thyroid hormone synthesis, Decreased
AOP:272Deposition of energy leading to lung cancerCancerWPHA/WNT Endorsed0.14KE:155Inadequate DNA repair
AOP:274Histone deacetylase inhibition leads to impeded craniofacial developmentMusculoskeletal System Disease-0.25KE:1558Collagen production, reduced
AOP:277Impaired IL-1R1 signaling leading to Impaired T-Cell Dependent Antibody ResponseImmune System DiseaseWPHA/WNT Endorsed0.25KE:202Inhibition, Nuclear factor kappa B (NF-kB)
AOP:278IKK complex inhibition leading to liver injuryUnclassified-0.12KE:202Inhibition, Nuclear factor kappa B (NF-kB)
AOP:288Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals)Endocrine System Disease-0.12KE:1614Decrease, androgen receptor activation
AOP:296Oxidative DNA damage leading to chromosomal aberrations and mutationsGenetic Disease; Chromosomal DiseaseWPHA/WNT Endorsed0.2KE:155Inadequate DNA repair
AOP:303Frustrated phagocytosis-induced lung cancerCancerUnder Development0.14KE:1669Increased, DNA damage and mutation
AOP:322Alkylation of DNA leading to reduced sperm countReproductive System Disease-0.2KE:155Inadequate DNA repair
AOP:328Excessive reactive oxygen species production leading to mortality (2)Unclassified-0.2KE:1770Decrease, Mitochondrial membrane potential
AOP:363Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structureUnclassifiedUnder Review0.12KE:277Thyroid hormone synthesis, Decreased
AOP:364Thyroperoxidase inhibition leading to altered visual function via decreased eye sizeUnclassifiedUnder Development0.12KE:277Thyroid hormone synthesis, Decreased
AOP:365Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterningUnclassifiedUnder Development0.12KE:277Thyroid hormone synthesis, Decreased
AOP:387Deposition of ionising energy leading to population decline via mitochondrial dysfunctionReproductive System Disease-0.12KE:1770Decrease, Mitochondrial membrane potential
AOP:397Bulky DNA adducts leading to mutationsGenetic DiseaseUnder Development0.33KE:155Inadequate DNA repair
AOP:409Frustrated phagocytosis leads to malignant mesotheliomaCancer-0.12KE:1669Increased, DNA damage and mutation
AOP:432Deposition of Energy by Ionizing Radiation leading to Acute Myeloid LeukemiaHematopoietic System Disease; Cancer-0.09KE:155Inadequate DNA repair
AOP:446PM-related Adverse outcome pathway frameworks on various systemsRespiratory System Disease-0.05KE:18Activation, AhR
AOP:451Interaction with lung resident cell membrane components leads to lung cancerCancer-0.11KE:1669Increased, DNA damage and mutation
AOP:457Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxineInherited Metabolic Disorder-0.17KE:277Thyroid hormone synthesis, Decreased
AOP:460Antagonism of Smoothened receptor leading to orofacial cleftingUnclassifiedUnder Development0.11KE:2043Decrease, Sonic Hedgehog second messenger production
AOP:478Deposition of energy leading to occurrence of cataractsNervous System Disease; Monogenic DiseaseUnder Review0.1KE:155Inadequate DNA repair
AOP:491Decrease, GLI1/2 target gene expression leads to orofacial cleftingUnclassifiedUnder Development0.17KE:2043Decrease, Sonic Hedgehog second messenger production
AOP:495Androgen receptor activation leading to prostate cancerReproductive System Disease; Cancer-0.11KE:286Altered, Transcription of genes by the androgen receptor
AOP:496Androgen receptor agonism leading to reproduction dysfunction （in zebrafish）Unclassified-0.1KE:286Altered, Transcription of genes by the androgen receptor
AOP:510Demethylation of PPAR promotor leading to vascular disrupting effectsCardiovascular System Disease-0.1KE:2165Activation of PPAR
AOP:513Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathwayCancer-0.2KE:233Decreased, PPAR-gamma activation

Associated AOPs with Level of Relevance 2
AOP Identifier AOP Title AO Classification OECD Status Coverage Score KE Identifier KE Name
AOP:43Disruption of VEGFR Signaling Leading to Developmental DefectsUnclassifiedWPHA/WNT Endorsed0.2KE:1001Increased, Developmental Defects

Associated AOPs with Level of Relevance 3
AOP Identifier AOP Title AO Classification OECD Status Coverage Score KE Identifier KE Name
AOP:19Androgen receptor antagonism leading to adverse effects in the male foetus (mammals)Reproductive System Disease-0.4KE:26Antagonism, Androgen receptor
KE:286Altered, Transcription of genes by the androgen receptor
AOP:27Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11)Gastrointestinal System DiseaseUnder Development0.12KE:41Inhibition, Bile Salt Export Pump (ABCB11)
AOP:30Estrogen receptor antagonism leading to reproductive dysfunctionUnclassifiedUnder Review0.17KE:112Antagonism, Estrogen receptor
AOP:36Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to SteatosisGastrointestinal System Disease; Inherited Metabolic Disorder-0.12KE:233Decreased, PPAR-gamma activation
AOP:111Decrease in androgen receptor activity leading to Leydig cell tumors (in rat)Cancer; Reproductive System Disease-0.2KE:1614Decrease, androgen receptor activation
AOP:120Inhibition of 5α-reductase leading to Leydig cell tumors (in rat)Cancer; Reproductive System Disease-0.2KE:1617Inhibition, 5α-reductase
AOP:123Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcriptionUnclassified-0.27KE:799Increased, HIF-1 heterodimer
KE:801modulation, Unknown
KE:802Increased, HIF-1 alpha transcription
AOP:128Kidney dysfunction by decreased thyroid hormoneUrinary System DiseaseUnder Development0.09KE:277Thyroid hormone synthesis, Decreased
AOP:131Aryl hydrocarbon receptor activation leading to uroporphyriaInherited Metabolic DisorderWPHA/WNT Endorsed0.17KE:18Activation, AhR
AOP:151AhR activation leading to preeclampsiaCardiovascular System DiseaseUnder Development0.14KE:18Activation, AhR
AOP:289Inhibition of 5α-reductase leading to impaired fecundity in female fishUnclassifiedUnder Development0.17KE:1617Inhibition, 5α-reductase
AOP:300Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in MammalsCognitive DisorderUnder Development0.2KE:1656Antagonism, Thyroid Receptor
AOP:3055α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspringUnclassifiedUnder Development0.6KE:1617Inhibition, 5α-reductase
KE:1614Decrease, androgen receptor activation
KE:286Altered, Transcription of genes by the androgen receptor
AOP:306Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspringUnclassifiedUnder Development0.75KE:1614Decrease, androgen receptor activation
KE:26Antagonism, Androgen receptor
KE:286Altered, Transcription of genes by the androgen receptor
AOP:310Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHRUnclassified-0.08KE:18Activation, AhR
AOP:344Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspringUnclassifiedUnder Development0.75KE:1614Decrease, androgen receptor activation
KE:26Antagonism, Androgen receptor
KE:286Altered, Transcription of genes by the androgen receptor
AOP:345Androgen receptor (AR) antagonism leading to decreased fertility in femalesEndocrine System Disease; Reproductive System Disease; Reproductive System DiseaseUnder Development0.5KE:1614Decrease, androgen receptor activation
KE:26Antagonism, Androgen receptor
KE:286Altered, Transcription of genes by the androgen receptor
AOP:372Androgen receptor antagonism leading to testicular cancerEndocrine System Disease; Reproductive System Disease; Cancer-0.6KE:1614Decrease, androgen receptor activation
KE:26Antagonism, Androgen receptor
KE:286Altered, Transcription of genes by the androgen receptor
AOP:414Aryl hydrocarbon receptor activation leading to lung fibrosis through TGF-β dependent fibrosis toxicity pathwayMusculoskeletal System Disease; Respiratory System Disease-0.2KE:18Activation, AhR
AOP:415Aryl hydrocarbon receptor activation leading to lung fibrosis through IL-6 toxicity pathwayMusculoskeletal System Disease; Respiratory System Disease-0.2KE:18Activation, AhR
AOP:416Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathwayCancer-0.33KE:18Activation, AhR
KE:1669Increased, DNA damage and mutation
AOP:417Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathwayCancer-0.4KE:18Activation, AhR
KE:1669Increased, DNA damage and mutation
AOP:418Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathwayRespiratory System Disease-0.2KE:18Activation, AhR
AOP:419Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathwayRespiratory System Disease-0.5KE:18Activation, AhR
KE:1923Altered gene expression, P53 dependent apoptosis pathway
AOP:420Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathwayCancer-0.25KE:18Activation, AhR
AOP:439Activation of the AhR leading to metastatic breast cancerThoracic Disease; CancerUnder Development0.11KE:18Activation, AhR
AOP:440Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasiaBenign Neoplasm; Endocrine System Disease; Reproductive System Disease; Reproductive System Disease; Cancer; Endocrine System DiseaseUnder Development0.11KE:1046Suppression, Estrogen receptor (ER) activity
AOP:443DNA damage and mutations leading to Metastatic Breast CancerThoracic Disease; CancerUnder Development0.3KE:1669Increased, DNA damage and mutation
KE:155Inadequate DNA repair
KE:112Antagonism, Estrogen receptor
AOP:447Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathwaysUrinary System Disease-0.17KE:202Inhibition, Nuclear factor kappa B (NF-kB)
KE:1770Decrease, Mitochondrial membrane potential
AOP:458AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in MammalsCognitive Disorder-0.12KE:18Activation, AhR
AOP:459AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in MammalsCognitive Disorder-0.22KE:18Activation, AhR
KE:277Thyroid hormone synthesis, Decreased
AOP:477Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspringPhysical Disorder-0.67KE:1614Decrease, androgen receptor activation
KE:26Antagonism, Androgen receptor
AOP:485Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognitionCognitive Disorder-0.14KE:1656Antagonism, Thyroid Receptor
AOP:493ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesityAcquired Metabolic Disease-0.1KE:2126Estrogen receptor alpha inactivation
AOP:494AhR activation leading to liver fibrosisGastrointestinal System Disease-0.17KE:18Activation, AhR
AOP:497ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndromeInherited Metabolic Disorder; Disease Of Metabolism-0.12KE:2126Estrogen receptor alpha inactivation
AOP:525Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memoryDevelopmental Disorder Of Mental Health-0.23KE:1656Antagonism, Thyroid Receptor
KE:2216Binding of antagonist to thyroid hormone receptor
KE:2220Antagonism, Glucocorticoid hormone receptor
AOP:563Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosisReproductive System Disease; Endocrine System Disease-0.17KE:18Activation, AhR

Associated AOPs with Level of Relevance 5
AOP Identifier AOP Title AO Classification OECD Status Coverage Score KE Identifier KE Name
AOP:21Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2UnclassifiedWPHA/WNT Endorsed0.4KE:18Activation, AhR
KE:947Increase, Early Life Stage Mortality
AOP:150Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGFUnclassifiedWPHA/WNT Endorsed0.29KE:18Activation, AhR
KE:947Increase, Early Life Stage Mortality
AOP:455Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial developmentMusculoskeletal System DiseaseUnder Review0.33KE:18Activation, AhR
KE:947Increase, Early Life Stage Mortality
AOP:456Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicityUnclassifiedUnder Review0.33KE:18Activation, AhR
KE:947Increase, Early Life Stage Mortality
DISCLAIMER

TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.